has partnered in a strategic global collaboration to develop and commercialise oral ziftomenib, an investigational menin inhibitor, to treat acute myeloid leukaemia (AML) and other haematologic malignancies. Kura will receive a $330m upfront payment and up to $420m in near-term milestone payments, including when the therapy launches in the monotherapy relapsed/refractory (R/R) setting. The gold standard of business intelligence.
Kura may also earn up to $741m in development, regulatory and commercial milestones, bringing the total potential payments to $1.161bn, including the opt-in for solid tumours. Kura will spearhead the development, regulatory strategies and manufacturing of ziftomenib in the US.
The companies will partner on commercial activities based on a joint US territory plan, sharing profits and losses equally. Kyowa Kirin will lead development and commercialisation outside the US, with Kura receiving tiered double-digit royalties on net sales. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Kura is also conducting trials to assess ziftomenib in conjunction with current standards of care for newly diagnosed and R/R NPM1-mutan.
:upscale()/2024/11/21/934/n/1922729/tmp_77sMIG_cd43fc068bb98f2c_GettyImages-2163917928.jpg)
